We license strain and process together, because a strain without its process is not a product.
The process that makes the strain economic, whether it runs heterotrophically in fermenters or photoautotrophically in light-driven systems: media formulation, including formulations built on agro-industrial side streams, feeding and control strategy, harvest and downstream route.
All catalogue strains are available for licensing now, with commercial specification set jointly with the licensee.
They are non-GMO Chlorella sp. and sit outside the scope of the EU Novel Food Regulation. Beyond the catalogue we work across microalgae more broadly, Euglena and Scenedesmus among them, and on strains you already hold. Regulatory status varies by species, and we establish it during scoping. Identities and process detail under NDA, with fields of use, territories and exclusivity negotiable.
Licenses are built around an upfront technology access fee plus a running royalty linked to production volume or net sales, scaled to the field of use, the territory and the degree of exclusivity granted. Where a strain or process needs development before it fits your specification, that work is quoted separately as a fixed-fee project, and what you pay for it reduces the upfront fee.
No. Every strain in our portfolio is non-GMO, developed through selection, adaptation and non-recombinant improvement methods. This is a deliberate strategic choice, not a limitation we work around.
Our platforms sit at different stages, from laboratory validation through to industrial production with a licensee. We state the current stage of each platform openly in the technical dossier and we do not present development-stage results as commercial performance.
Most of our processes run on conventional stirred-tank fermentation and standard downstream unit operations, and we work photoautotrophically where that suits the strain. Rather than hand you a specification and leave you to it, we assess what you already have during scoping and tell you exactly what, if anything, needs to change.
Case dependent. Depending on the strain and the process, protection rests on some combination of trade secret over strain and know-how, filed applications, and contractual restrictions in the licence. We set out which applies to your platform during scoping. Licensees receive defined use rights rather than ownership.
Yes, within a defined field of use and territory, typically in exchange for minimum performance commitments.
Usually not. We work by preference with strains that carry no novel food barrier in the intended market, so the regulatory path is clear before a licence is signed. Where a target does carry a constraint, we say so during scoping rather than afterwards. Placing the final product on the market remains the licensee’s responsibility, and we support the technical dossier behind it.
PhycoFerm Lda., Universidade do Algarve, Campus de Gambelas, Faro, Portugal
You want to buy the ingredient, not make it. Bioactive ingredient sales and custom formulations. Go to ingredients
You have a target we have not developed yet. Fixed fee, fixed timeline, full technical handover, and you own complete commercial rights to what we deliver. No royalties. Go to services